Cocrystal Pharma (COCP, Financial) has announced significant progress in the development of its drug candidate CDI-988, aimed at combating norovirus infections. The compound has demonstrated strong binding to the GII.17 protease, a region known for its high conservation. This efficacy is paralleled by its performance against various GII.4 norovirus variants, which dominated globally until recently.
The findings were achieved using the company's proprietary structure-based technology platform, which enabled detailed analysis of the GII.17 protease's crystal structures. This advancement sets the stage for Cocrystal to proceed with a human norovirus challenge study in the United States, slated for 2025. The goal of this study is to assess CDI-988’s potential as both a preventive measure and treatment for norovirus infections.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 3 analysts, the average target price for Cocrystal Pharma Inc (COCP, Financial) is $8.33 with a high estimate of $10.00 and a low estimate of $7.00. The average target implies an upside of 489.51% from the current price of $1.41. More detailed estimate data can be found on the Cocrystal Pharma Inc (COCP) Forecast page.
Based on the consensus recommendation from 2 brokerage firms, Cocrystal Pharma Inc's (COCP, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
